ISRCTN15406513进行中（未招募）1 期
A phase Ib, randomized, double-blind, placebo-controlled, single-center study to evaluate the safety and pharmacokinetics of multiple ascending doses of GDC-6988 with and without albuterol pretreatment in healthy adult subjects
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 18 - 55 years at time of signing Informed Consent Form
- •2. Body mass index of 18 - 32 kilograms per square metre (kg/m²) at screening
- •3. Body temperature of 35°C - 37.5°C at screening and at Day-1
- •4. Systolic blood pressure of 90 - 150 millimetres of mercury (mmHg) and diastolic blood pressure of 50 - 95 mmHg at screening and at Day-1. Blood pressure should be measured while the participant is in a seated position.
- •5. Forced expiratory volume in 1 second (FEV1) >80% of predicted at screening and at Day-1
- •6. Forced vital capacity (FVC) >2.0 L by spirometry at screening
排除标准
- •1. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of study drug
- •2. Treatment with investigational therapy (or blinded comparator) within 90 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
- •3. Treatment with any immunosuppressive medication within 28 days or 5 drug elimination half-lives, whichever is longer, prior to initiation of study drug
- •4. Treatment with an herbal or homoeopathic remedy within 14 days or 5 drug elimination half-lives (whichever is longer) prior to initiation of study drug
- •5. Treatment with any vaccine within 14 days prior to initiation of study drug or a scheduled vaccination during study period (through the follow-up/early termination visit)
- •6. Positive for tuberculosis (TB) during screening or within 3 months prior to screening, defined as a positive QuantiFERON®-TB Gold test (QFT)
- •7. Positive human immunodeficiency virus (HIV) test at screening
- •8. Positive hepatitis B surface antigen (HBsAg) test at screening
- •9. Positive hepatitis C virus (HCV) antibody test at screening
- •10. Receipt of blood products within 120 days prior to screening
- •11. Hospitalisation within 28 days prior to initiation of study drug
- •12. Anticipation of need for a surgical procedure during the study
- •13. Infection requiring oral or intravenous (IV) antibiotics within 28 days prior to screening or any evidence of current infection (e.g., bacterial, viral, fungal)
- •14. Upper or lower respiratory tract infection within 2 weeks prior to initiation of study drug
- •15. Documented physician-diagnosed asthma for at least 12 months prior to screening
- •16. Post-bronchodilator reversibility of FEV1 (litres) =12% and =200 mL at screening
- •17. Any medical condition or abnormal clinical laboratory finding that, in the investigator's judgement, would preclude the participant's safe participation in and completion of the study or could affect the interpretation of the results
- •18. History of malignancy within 5 years prior to screening, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer
- •19. History of any significant drug or food allergy (e.g., allergic reactions that resulted in anaphylaxis or hepatotoxicity)
- •20. History of symptomatic bradycardia
- •21. History of ataxia or condition associated with ataxia
- •22. Abnormally low total lung capacity, defined as <80% of predicted for participants of European descent or <75% of predicted for participants of non-European descent, at screening
- •23. Diffusion capacity of the lung for carbon monoxide, defined as <75% of predicted for participants of European descent or <70% of predicted for participants of non-European descent, at screening
- •24. Glomerular filtration rate <80 millilitres per minute (mL/min)/1.73 square metre (m^2) as calculated through use of the Chronic Kidney Disease Epidemiology Collaboration equation. Participants with a glomerular filtration rate =80 mL/min/1.73 m² and <90 mL/min/1.73 m² are eligible only if have confirmed cystatin C value below upper limit of normal (ULN)
研究者
相似试验
进行中（未招募）
1 期
Efficacy and safety study of SPX-001 for influenza in participating healthy adultsInfluenza virusInfections and InfestationsISRCTN52435761SpectrumX Medical Limited50
已完成
1 期
A blinded study in healthy volunteers to evaluate the safety of the test medicine and compare how the test medicine behaves when the dosage is increased, and when taken alone or alongside salbutamol (albuterol)Cystic fibrosis (CF)Nutritional, Metabolic, EndocrineCystic fibrosisISRCTN30841680F. Hoffman-La Roche Ltd.41
已完成
不适用
A Phase Ib, double-blind, randomized, placebo-controlled trial in genotype 1 HCV-infected patients to determine the safety, tolerability, pharmacokinetics and antiviral activity of repeated doses of TMC649128 given as monotherapy and given in combination with pegylated interferon + ribavirihepatitis C10047438liver diseaseNL-OMON35874PRA International EDS30
已完成
不适用
A Phase Ib, Randomized, Double-Blind, Placebo Controlled, Sequential Study of Single Oral Doses of M5717 to Explore the Chemoprophylactic Activity of M5717 in a Controlled Plasmodium falciparum Sporozoite Challenge Model in Healthy Participantsmalaria10014142NL-OMON49971Merck50
已完成
不适用
A phase Ib double-blind, placebo-controlled, randomized, dose-escalating trial to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of repeated subcutaneous injections of MT203 in patients with mild to moderate rheumatoind arthritis (RA) on treatment with methotrexate.10003816rheumatoid arthritisRANL-OMON38054Takeda12